# Super-ARMS® *EGFR* Mutation Detection Kit

**Detection of 42 mutations in exons 18-21**

Instruction for Use

| | | | |
|---|---|---|---|
| REF 8.01.20213X012E | 12 tests | For Stratagene Mx3000P™, ABI7500, LightCycler 480, cobas® z480, SLAN-96S | |

**Amoy Diagnostics Co., Ltd.**
39 Dingshan Road, Haicang District,
Xiamen 361027, P. R. China
Tel: +86 592 6806835
Fax: +86 592 6806839
E-mail: sales@amoydx.com
Website: http://www.amoydx.com

EC REP **Wellkang Ltd**
Suite B, 29 Harley Street,
London W1G 9QR United Kingdom

Version: B1.4
January 2020

## Background

Due to its association with malignancies, epidermal growth factor receptor (EGFR) has become the target of an expanding class of anticancer therapies, such as gefitinib (Iressa) and erlotinib (Tarceva), which are tyrosine kinase inhibitors (TKIs). These drugs work best on patients whose cancer is driven by abnormal EGFR signaling. Non-small cell lung cancer (NSCLC) patients who experienced rapid, durable, complete or partial responses to TKIs therapy have been found to harbor somatic mutations in the *EGFR* gene. Cancer patients with somatic *EGFR* mutations have shown an impressive 60% response rate, much higher than that for conventional chemotherapy. Therefore, detection of the *EGFR* mutation status in tumor tissue is key to offering tailored, personalized treatment to cancer patients. Resistance to therapy, either in the primary tumor or acquired after TKI treatment, is also associated with somatic mutations.

Both tumor tissue and peripheral blood samples can be used for *EGFR* mutation detection. Currently, tumor tissue is the most frequent specimen for *EGFR* mutation testing. In meanwhile, it is demonstrated that there is cell-free DNA of the apoptotic and necrotic tumor cell existing in peripheral blood. Noninvasive detection of *EGFR* mutation in circulating tumor DNA (ctDNA) extracted from plasma has been proved to be feasible as re-biopsy of tumor tissue was challenging.

## Intended Use

The Super-ARMS® *EGFR* Mutation Detection Kit is a real-time PCR assay for qualitative detection of 42 somatic mutations in exons 18, 19, 20 and 21 of *EGFR* gene in human genomic DNA extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue or circulating DNA extracted from plasma sample. The kit is intended to be used to assess *EGFR* mutation status in NSCLC patients and aid in identifying patients who may response to the treatment with *EGFR*-TKI.

The kit is for *in vitro* diagnostic use, and intended to be used by trained professionals in a laboratory environment.

## Principles of the Procedure

The kit adopts Amplification Refractory Mutation System (ARMS) and real-time PCR technology, which comprises specific primers and fluorescent probes to detect *EGFR* mutations in human genomic DNA and circulating DNA. During the nucleic acid amplification, the targeted mutant DNA is matched with the bases at 3' end of the primer, amplified selectively and efficiently, then the mutant amplicon is detected by fluorescent probes labeled with FAM. While the wild-type DNA cannot be matched with specific primers, there is no amplification occurs.

The kit is composed of **P-*EGFR* Reaction Mix**, **P-*EGFR* Enzyme Mix** and **P-*EGFR* Positive Control**.

1) The contents in **P-*EGFR* Reaction Mix A** and **P-*EGFR* Reaction Mix B** formed a mutation detection system and an internal control system. The mutation detection system includes primers and FAM/ROX/CY5-labeled probes specific for designated *EGFR* mutations, to detect the *EGFR* mutation status. The internal control system contains the primers and HEX-labeled probe for a region of genomic DNA without known mutations and polymorphism, to detect the presence of inhibitors and monitor the accuracy of experimental operation.
2) The **P-*EGFR* Positive Control** contains recombinant gene with *EGFR* mutations.
3) The **P-*EGFR* Enzyme Mix** contains Taq DNA polymerase for PCR amplification and uracil-N-glycosylase which works at room temperature to prevent PCR amplicon carryover contamination.

## Kit Contents

This kit contains the following materials (see Table 1):

Table 1 Kit Contents

| Contents | Main Ingredient | Quantity |
|---|---|---|
| **P-*EGFR* Reaction Mix A** | Buffer, $Mg^{2+}$ | 1540 μL/tube ×2 |
| **P-*EGFR* Reaction Mix B1** | Primers, Probes, dNTPs | 140 μL/tube ×1 |
| **P-*EGFR* Reaction Mix B2** | Primers, Probes, dNTPs | 140 μL/tube ×1 |
| **P-*EGFR* Reaction Mix B3** | Primers, Probes, dNTPs | 140 μL/tube ×1 |
| **P-*EGFR* Reaction Mix B4** | Primers, Probes, dNTPs | 140 μL/tube ×1 |
| **P-*EGFR* Enzyme Mix** | Taq DNA Polymerase, Uracil-N-Glycosylase | 30 μL/tube ×1 |
| **P-*EGFR* Positive Control** | Plasmid DNA | 400 μL/tube ×1 |

The detailed detection information is listed in Table 2.

Table 2 Detection Information

| Reagent | Mutation detected | Fluorescent Signal | | | |
|---|---|---|---|---|---|
| | | FAM | HEX | ROX | CY5 |
| **P-*EGFR* Reaction Mix A**<br>**P-*EGFR* Reaction Mix B1** | 19-Del/ L858R | 19-Del | IC | L858R | / |
| **P-*EGFR* Reaction Mix A**<br>**P-*EGFR* Reaction Mix B2** | T790M | T790M | IC | / | / |
| **P-*EGFR* Reaction Mix A**<br>**P-*EGFR* Reaction Mix B3** | G719X/ L861Q/S768I | G719X | IC | L861Q | S768I |
| **P-*EGFR* Reaction Mix A**<br>**P-*EGFR* Reaction Mix B4** | 20-Ins | 20-Ins | IC | / | / |

* IC: Internal Control

## Storage and Stability

The kit requires shipment on frozen ice packs. All contents of the kit should be stored immediately upon receipt at -20±5℃ and protected from light.

The shelf-life of the kit is eight months. The recommend maximum freeze-thaw cycle is five cycles.

## Additional Reagents and Equipment Required but Not Supplied

1) Compatible PCR instruments:
   Stratagene Mx3000P™, ABI7500, LightCycler480, cobas® z480, or SLAN-96S.
2) DNA Extraction kit. We recommend use of AmoyDx® FFPE DNA Kit (Cat No.: 8.02.23501X036G) for FFPE tissues, AmoyDx® Circulating DNA kit (Cat No.: 8.02.26201X024G) for plasma sample.
3) Spectrophotometer for measuring FFPE DNA concentration.
4) Mini centrifuge with rotor for centrifuge tubes.
5) Mini centrifuge with rotor for PCR tubes.
6) Nuclease-free centrifuge tubes.
7) Nuclease-free PCR tubs and caps.
8) Adjustable pipettors and filtered pipette tips for handling DNA.
9) Tube racks.
10) Disposable powder-free gloves.
11) Sterile, nuclease-free water.
12) 1×TE buffer (pH 8.0).

## Precautions and Handling Requirements

**For *in vitro* diagnostic use.**

### Precautions

- Please read the instruction carefully and become familiar with all components of the kit prior to use, and strictly follow the instruction during operation.
- Please check the compatible real-time PCR instruments prior to use.
- DO NOT use the kit or any kit component after their expiry date.
- DO NOT use any other reagents from different lots in the tests.
- DO NOT use any other reagent in the other test kits.

### Safety Information

- Handle all specimens and components of the kit as potentially infectious material using safe laboratory procedures.
- Only trained professionals can use this kit. Please wear suitable lab coat and disposable gloves while handling the reagents.
- Avoid skin, eyes and mucous membranes contact with the chemicals. In case of contact, flush with water immediately.
- DO NOT pipet by mouth.

### Decontamination and Disposal

- The kit contains positive control; strictly distinguish the positive control from other reagents to avoid contamination which may cause false positive.
- PCR amplification is extremely sensitive to cross-contamination. The flow of tubes, racks, pipets and other materials used should be from pre-amplification to post-amplification, and never backwards.
- Gloves should be worn and changed frequently when handling samples and reagents to prevent contamination.
- Using separate, dedicated pipettes and filtered pipette tips when handling samples and reagents to prevent exogenous DNA contamination to the reagents.
- Please pack the post-amplification tubes with two disposable gloves and discard properly. DO NOT open the post- amplification PCR tubes.
- All disposable materials are for one time use. DO NOT reuse
- The unused reagents, used kit, and waste must be disposed of properly.

### Cleaning

- After the experiment, wipe down the work area, spray down the pipettes and equipment with 75% ethanol or 10% hypochlorous acid solution.

### Instrument Setup

- Setup the reaction volume as 80 μL.
- For Stratagene Mx3000P™, if there's low net fluorescence signal (dR) but high background signal (R), please reduce the signal gain setting of instrument properly. We recommend set up the Fliter Set Gain Settings of FAM, HEX, ROX, CY5 as 4, 4, 1, 4 respectively.
- For ABI 7500, please set up as follows: Reporter Dye: FAM, VIC, ROX, CY5; Quencher Dye: TAMRA; Passive Reference: NONE.
- For LightCycler480 and cobas® z480 instrument, it's necessary to conduct Color Compensation prior to the first use according to Color Compensation instructions. Please contact AmoyDx Technical Support or Account Manager to get the Super-ARMS® EGFR Color Compensation Kit and Color Compensation instructions.
- For SLAN-96S, please set up as follows: Probe mode: FAM, VIC, ROX, CY5. During the result analysis, open the "Preference" window, in "Chart Options" section; select "Selected Wells" for "Y-Axis Scaling Auto-adjust By" and "Absolute Fluorescence Value Normalization" for "Amplification Curve". We recommend set up the Gain of FAM, HEX, ROX, CY5 as 1, 2.5, 2, 7 respectively.
- Refer to the real-time PCR instrument operator's manual for detailed instructions.
- We recommend that all PCR instruments in use should be conducted fluorescence calibration once a year.

## Assay Procedure

### 1. DNA Extraction

The specimen material must be human genomic DNA extracted from FFPE tissue or circulating DNA extracted from plasma sample in NSCLC patients. DNA extraction reagents are not included in the kit. Before DNA extraction, it's essential to use standard pathology methodology to ensure tumor sample quality. Carry out the DNA extraction according to the instructions of DNA extraction kit.

Tumor samples are non-homogeneous, may also contain non-tumor tissue. Data from different tissue sections of the same tumor may be inconsistent. DNA from non-tumor tissue would not be detected with *EGFR* mutations. It's better to use tumor tissue samples with more than 30% tumor cells.

The $OD_{260}/OD_{280}$ value of extracted DNA from FFPE tissue should be between 1.8 ~ 2.0 (measured using the spectrophotometer, the NanoDrop 1000 /2000 spectrophotometer is recommended).

The amount of extracted DNA from FFPE tissue used for PCR amplification is shown in Table 3. And the circulating DNA isolated from plasma should be used directly without dilution.

Table 3 Recommended DNA concentration

| Tissue | Storage time | DNA concentration | DNA amount per reaction |
|---|---|---|---|
| FFPE sample | ≤ 3 years | 1 ng/μL | 15 ng |

***Note:***

- *The FFPE tissue should be handled and stored properly, and the storage time should preferably be less than 3 years.*
- *The plasma sample should be derived from EDTA anti-coagulated peripheral whole blood. The recommended volume of whole blood is no less than 10 mL.*
- *The extracted DNA should be used immediately, if not, it should be stored at -20±5℃ for no more than 3 months.*
- *Before detection, dilute the extracted tissue DNA with 1×TE buffer (pH 8.0) to designated concentration. We recommend using at least 5 μL DNA for 10 times dilution, to ensure the validity of final concentration.*

## 2. Mutation Detection

1) Take the **P-*EGFR* Positive Control**, **P-*EGFR* Reaction Mix (A, B1~B4)** and **P-*EGFR* Enzyme Mix** out of the kit from the freezer.
2) Thaw the **P-*EGFR* Positive Control** and **P-*EGFR* Reaction Mix (A, B1~B4)** at room temperature. When the reagents are completely thawed, invert each tube for 10 times and centrifuge briefly to collect all liquid at the bottom of the tube.
3) Briefly centrifuge **P-*EGFR* Enzyme Mix** prior to use.
4) Prepare sufficient P-*EGFR* Master Mix 1~4 containing P-EGFR Enzyme Mix, P-EGFR Reaction Mix A and P-EGFR Reaction Mix B (B1~B4 respectively) in separate sterile centrifuge tube respectively according to the ratio in Table 4. Mix each Master Mix thoroughly by gently pipetting up and down more than 10 times and centrifuge briefly.

Table 4 P-*EGFR* Master Mix 1~4

| Content | Volume per test (μL) |
|---|---|
| P-*EGFR* Reaction Mix A | 55 |
| P- *EGFR* Reaction Mix B (B1/B2/B3/B4) | 10 |
| P- *EGFR* Enzyme Mix | 0.48 |
| **Total** | **65.48** |

***Note:***

- *Every PCR run must contain one PC (Positive control) and one NTC (No template control).*
- *Do not vortex enzyme mix or any mixture with enzyme mix.*
- *The prepared mixtures should be used immediately, avoid prolonged storage.*
- *Due to the viscosity of the enzyme mix, pipet slowly to ensure all mix is completely dispensed from the tip.*
- *Pipet enzyme mix by placing the pipet tip just under the liquid surface to avoid the tip being coated in excess enzyme.*

5) Take out the sample DNA (see Table 3 for FFPE DNA concentration) and nuclease-free water for NTC.
6) Prepare four PCR tubes for NTC: Dispense 65.48 μL of P-*EGFR* Master Mix 1~4 to each PCR tube respectively. Then add 15 μL of nuclease-free water to each NTC tube and cap the PCR tubes.
7) Prepare four PCR tubes for each sample: Dispense 65.48 μL of P-*EGFR* Master Mix 1~4 to each PCR tube respectively. Then add 15 μL of each sample DNA to each sample tube and cap the PCR tubes.
8) Prepare four PCR tubes for PC: Dispense 65.48 μL of P-*EGFR* Master Mix 1~4 to each PCR tube respectively. Then add 15 μL of P-*EGFR* Positive Control to each PC tube and cap the PCR tubes.
9) Briefly centrifuge the PCR strips to collect all liquid at the bottom of each PCR tube.
10) Place the PCR strip tubes into the real-time PCR instrument. A recommended plate layout is shown in Table 5.

Table 5 PCR Plate Layout

| Well | 1 | 2 | 3 | 4 |
|---|---|---|---|---|
| **A** | Sample 1 | Sample 3 | Sample 5 | NTC |
| **B** | Sample 1 | Sample 3 | Sample 5 | NTC |
| **C** | Sample 1 | Sample 3 | Sample 5 | NTC |
| **D** | Sample 1 | Sample 3 | Sample 5 | NTC |
| **E** | Sample 2 | Sample 4 | Sample 6 | PC |
| **F** | Sample 2 | Sample 4 | Sample 6 | PC |
| **G** | Sample 2 | Sample 4 | Sample 6 | PC |
| **H** | Sample 2 | Sample 4 | Sample 6 | PC |

11) Setup the PCR Protocol using the cycling parameters in Table 6.

Table 6 Cycling Parameters

| Stage | Cycles | Temperature | Time | Data collection |
|---|---|---|---|---|
| 1 | 1 | 95℃ | 10min | / |
| 2 | 15 | 95℃ | 40s | / |
| | | 64℃ | 40s | / |
| | | 72℃ | 30s | / |
| 3 | 28 | 93℃ | 40s | / |
| | | 60℃ | 45s | FAM/ROX/CY5 and HEX/VIC |
| | | 72℃ | 30s | / |

12) Start the PCR run immediately.
13) When the PCR run finished, analyze the data according to the "Results Interpretation" procedures.

### 3. Results Interpretation

***Before mutation data analysis, the following items should be checked:***

1) For NTC: The FAM/ROX/CY5 signal of Reaction Mix 1~4 should be no amplification and Ct value should be ≥ 28, HEX/VIC Ct values of Reaction Mix 1~4 should be ≥ 22. If not, the data is *INVALID*. The sample should be retested.
2) For Positive control: for FAM and HEX/VIC signals, the Ct values of Reaction Mix 1~4 should be < 20; for ROX signal, the Ct values of Reaction Mix 1 and 3 should be < 20; for CY5 signal, the Ct value of Reaction Mix 3 should be < 20. If any of the above requirements is not met, the data is *INVALID*. The sample should be retested.
3) For the internal control assay for each sample: the HEX/VIC Ct values of Reaction Mix 1~4 should be < 19. If not, this indicates insufficient DNA or presence of PCR inhibitors. The sample should be retested with increased or re-extracted DNA.

***Analyze the mutation assay for each sample:***

4) Record the mutant FAM/ROX/CY5 Ct values of Reaction Mix 1~4.
5) Calculate the ΔCt value for each tube: **ΔCt value = Mutant Ct value (FAM/ROX/CY5) – HEX/VIC Ct value**
6) Result interpretation for each tube according to the Cut-off ΔCt value in Table 7.
   a) If the ΔCt value is < the Cut-off ΔCt value, the sample is determined as positive.
   b) If the ΔCt value is ≥ the Cut-off ΔCt value, the sample is determined as negative or under the LOD (limit of Detection) of the kit.
   c) Two or more *EGFR* mutations may be detected for a sample.

Table 7 Result Determination

| Tube No. | | | FAM | ROX | CY5 |
|---|---|---|---|---|---|
| Cut-off ΔCt value | 1 | 19-Del / L858R | 11 | 11 | / |
| | 2 | T790M | 8 | / | / |
| | 3 | G719X / L861Q / S768I | 12 | 12 | 12 |
| | 4 | 20-Ins | 11 | / | / |

## Performance Characteristics

The performance characteristics of this kit were validated on Stratagene Mx3000P™, ABI7500, LightCycler480, cobas® z480 and SLAN-96S.

1. Limit of Detection

The Limit of Detection (LOD) of the kit for each mutation is shown in Table 8.

Table 8 LOD for each EGFR mutation

| Exon | Mutation | Base Change | Cosmic ID | Name | LOD (%) |
|---|---|---|---|---|---|
| Exon 18 | G719A | 2156G>C | 6239 | E-18-M1 | 0.20% |
| | G719S | 2155G>A | 6252 | E-18-M2 | 0.80% |
| | G719C | 2155G>T | 6253 | E-18-M3 | 0.40% |
| Exon 19 | E746_A750del (1) | 2235_2249del15 | 6223 | E-19-M1 | 0.20% |
| | E746_A750del (2) | 2236_2250del15 | 6225 | E-19-M2 | 0.20% |
| | L747_P753>S | 2240_2257del18 | 12370 | E-19-M3 | 0.60% |
| | E746_T751>I | 2235_2252>AAT(complex) | 13551 | E-19-M4 | 0.40% |
| | E746_T751del | 2236_2253del18 | 12728 | E-19-M5 | 0.40% |
| | E746_T751>A | 2237_2251del15 | 12678 | E-19-M6 | 0.20% |
| | E746_S752>A | 2237_2254del18 | 12367 | E-19-M7 | 0.20% |
| | E746_S752>V | 2237_2255>T(complex) | 12384 | E-19-M8 | 0.20% |
| | E746_S752>D | 2238_2255del18 | 6220 | E-19-M9 | 0.40% |
| | L747_A750>P | 2238_2248>GC(complex) | 12422 | E-19-M10 | 0.40% |
| | L747_T751>Q | 2238_2252>GCA(complex) | 12419 | E-19-M11 | 0.20% |
| | L747_E749del | 2239_2247delTTAAGAGAA | 6218 | E-19-M12 | 0.40% |
| | L747_T751del | 2239_2253del15 | / | E-19-M13 | 0.40% |
| | L747_S752del | 2239_2256del18 | 6255 | E-19-M14 | 0.40% |
| | L747_A750>P | 2239_2248TTAAGAGAAG>C(complex) | 12382 | E-19-M15 | 0.40% |

| | | | | | |
|---|---|---|---|---|---|
| | L747_P753>Q | 2239_2258>CA(complex) | 12387 | E-19-M16 | 0.40% |
| | L747_T751>S | 2240_2251del12 | 6210 | E-19-M17 | 0.80% |
| | L747_T751del | 2240_2254del15 | 12369 | E-19-M18 | 0.40% |
| | L747_T751>P | 2239_2251>C(complex) | 12383 | E-19-M19 | 0.40% |
| | L747_T751del | 2238_2252del15 | 23571 | E-19-M20 | 0.40% |
| | L747_S752>Q | 2239_2256>CAA | 12403 | E-19-M21 | 0.80% |
| | E746_T751>V | 2237_2252>T | 12386 | E-19-M22 | 0.60% |
| | E746_T751>T | 2236_2253> ACG | / | E-19-M23 | 0.80% |
| | L747_A750>P | 2239_2250>CCC | / | E-19-M24 | 0.40% |
| | L747_K754>QL | 2239_2261>CAATT | / | E-19-M25 | 0.80% |
| | E746_K754>EQHL | 2238_2261>GCAACATCT | / | E-19-M26 | 0.40% |
| | E746_S752>EQ | 2238_2256>GCAA | / | E-19-M27 | 0.60% |
| | E746_A750>QP | 2236_2248>CAAC | 13557 | E-19-M28 | 0.60% |
| | E746_T751>Q | 2236_2253>CAA | 22999 | E-19-M29 | 0.40% |
| Exon 20 | T790M | 2369C>T | 6240 | E-20-M1 | 0.20% |
| | S768I | 2303G>T | 6241 | E-20-M2 | 0.20% |
| | H773_V774insH | 2319_2320insCAC | 12377 | E-20-M3 | 0.40% |
| | D770_N771insG | 2310_2311insGGT | 12378 | E-20-M4 | 0.60% |
| | V769_D770insASV | 2307_2308insGCCAGCGTG | 12376 | E-20-M5 | 0.60% |
| | D770_N771insSVD | 2311_2312insGCGTGGACA | 13428 | E-20-M8 | 0.40% |
| | V769_D770insASV | 2309_2310AC>CCAGCGTGGAT | 13558 | E-20-M9 | 0.40% |
| | H773_V774insNPH | 2319_2320insAACCCCCAC | 12381 | E-20-M10 | 0.80% |
| Exon 21 | L858R | 2573T>G | 6224 | E-21-M1 | 0.20% |
| | L861Q | 2582T>A | 6213 | E-21-M2 | 0.20% |

2. Cross-reactivity

The cross reaction among the mutant sequences targeted by this kit, the cross reaction with other homologous mutant nucleotide sequence (*HER2* gene, belongs to the same family as *EGFR* gene, the plasmids with five *HER2* hotspot mutations were selected in this study), the cross reaction with wild-type genomic DNA (DNA concentrations are 1~15 ng/reaction), and the cross reaction with non-human gene (the DNA was extracted from *Escherichia Coli*, *Yeast*, *Mycobacterium tuberculosis* and *Streptococcus pneumonia* which were common microorganism causing lung infection) were evaluated, the results shown no cross-reactions.

3. Interference factor

12 common interference substances: endogenous Hemoglobin, Ferritin, Albumin and Triglyceride, exogenous pathogenic microorganism such as *Mycobacterium Tuberculosis* and *Atreptococcus Pneumoniae*, *therapeutic drugs such as* Taxol, Carboplatin and Tarceva, common anticoagulants such as Heparin sodium, Sodium citrate and EDTA were evaluated in this study. It is confirmed that the potential maximum concentrations: 2 g/L hemoglobin, 37 mmol/L triglyceride, 200 ng/mL Ferritin, 60 g/L Albumin, $10^6$ CFU/mL *Mycobacterium Tuberculosis*, $10^6$ CFU/mL *Atreptococcus Pneumoniae*, 90 μg/mL Taxol, 90 μg/mL Carboplatin, 90 μg/mL Tarceva, 0.645 mol/L Sodium citrate and 27 μmol/L EDTA would not interfere with the test result. While 150 U/mL Heparin sodium would inhibit the test performance. It is stated in DNA Extraction section in the Instructions to avoid using *heparin anticoagulant.*

4. Precision

3 precision controls: negative control, weak positive control (with 1% mutant content) and strong positive control (with 50% mutant content) were used in the validation. 3 batches of the kits were tested with the precision controls by 2 operators twice a day for 20 days on different PCR instruments. The Ct values were calculated, the CV values were all within 5%.

## Limitations

1) The kit is to be used only by personnel specially trained with PCR techniques.
2) The results can be used to assist clinical diagnosis, combining with other clinical and laboratory findings.
3) The kit has been validated for use with circulating DNA extracted from plasma sample and human genomic DNA extracted from FFPE tissue.
4) Reliable results are dependent on proper specimen collection, processing, transport, and storage.
5) The sample containing degraded DNA may affect the ability of the test to detect *EGFR* mutation.
6) This kit can only assess the *EGFR* mutation status and detect 42 *EGFR* mutations indicated above.
7) Samples with negative result (No mutation detected) may harbor *EGFR* mutations not detected by this assay.

## References

1) Shama SV, Bell DW, Settleman J, et al; Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 2007,7(3):169-81.
2) Ressel R, Moran T, Queralt C, et al; Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med, 2009,361(10):958-67.
3) Mork Ts, Wu YL, Thongprasert S, et al; Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009,361(10):947-57.
4) Gazdar AF; Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med, 2009, 361(10):1018-20.
5) Dancey JE; Epidermal growth factor receptor inhibitors in non-small cell lung cancer. Drugs, 2007, 67(8):1125-38.
6) Kobayashi S, Boggon TJ, Dayaram T, et al; *EGFR* mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med, 2005, 352(8):786-92.
7) Yasuda H., S kobayshi, Costa, D. B, et al. *EGFR* exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol，2012, 13(1): e23-31.
8) Kimura H, Suminoe M, Kasahara K, et al; Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer, 2007, 97(6): 778-784.
9) Huang Z, Wang ZJ, Bai H, et al; The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. Thoracic Cancer, 2012, 3(4): 334-340.

## Symbols

| | | | |
|---|---|---|---|
| EC REP | Authorized Representative in the European Community | IVD | In Vitro Diagnostic Medical Device |
| | Manufacturer | REF | Catalogue Number |
| LOT | Batch Code | | Use By |
| Σ | Contains Sufficient for <n> Tests | | Temperature Limitation |
| | Consult Instructions For Use | | Keep Dry |
| | This Way Up | | Fragile, Handle With Care |